Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial.
Researchers have randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, Hydroxyurea, or both to receive either more intensive treatment ( target hematocrit, less than 45% ) ( low-hematocrit group ) or less intensive treatment ( target hematocrit, 45 to 50% ) ( high-hematocrit group ).
The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascular events, cardiovascular hospitalizations, incidence of cancer, progression to myelofibrosis, myelodysplasia or leukemic transformation, and hemorrhage.
An intention-to-treat analysis was performed.
After a median follow-up of 31 months, the primary end point was recorded in 5 of 182 patients in the low-hematocrit group ( 2.7% ) and 18 of 183 patients in the high-hematocrit group ( 9.8% ) ( hazard ratio in the high-hematocrit group, HR=3.91; P=0.007 ).
The primary end point plus superficial-vein thrombosis occurred in 4.4% of patients in the low-hematocrit group, as compared with 10.9% in the high-hematocrit group ( HR=2.69; P=0.02 ).
Progression to myelofibrosis, myelodysplasia or leukemic transformation, and bleeding were observed in 6, 2, and 2 patients, respectively, in the low-hematocrit group, as compared with 2, 1, and 5 patients, respectively, in the high-hematocrit group.
There was no significant between-group difference in the rate of adverse events.
In conclusion, in patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with a hematocrit target of 45 to 50%. ( Xagena )
Marchioli R et al, N Engl J Med 2013; 368:22-33